Trial reportThe Journal of clinical psychiatry2019
A Randomized Placebo-Controlled Trial of Omega-3 and Sertraline in Depressed Patients With or at Risk for Coronary Heart Disease.
Trial report in The Journal of clinical psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02021669 (Omega-3 for Depression and Other Cardiac Risk Factors-2), which is not on this map. Cited by 24 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Omega-3 for Depression and Other Cardiac Risk Factors-2
Who cites it
24 citing papers in PubMed, 7 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Nutraceuticals and phytoceuticals for the treatment of major depressive disorder: a systematic review and network meta-analysis.Molecular psychiatry · 2026Pooled it
- Omega-3 fatty acid supplementation for depression in children and adolescents.The Cochrane database of systematic reviews · 2024Pooled it
- Efficacy and safety of omega-3 fatty acids supplementation for anxiety symptoms: a systematic review and dose-response meta-analysis of randomized controlled trials.BMC psychiatry · 2024Pooled it
- Omega-3 PUFAs' efficacy in the therapy of coronary artery disease combined with anxiety or depression: a meta-analysis.Frontiers in psychiatry · 2024Pooled it
- Psychological and pharmacological interventions for depression in patients with coronary artery disease.The Cochrane database of systematic reviews · 2021Pooled it
- Omega-3 fatty acids for depression in adults.The Cochrane database of systematic reviews · 2021Pooled it
- Pooled it
- Neurocardiology: Brain-Heart Interactions in the Heart.MedComm · 2026Review
- Omega-3 Polyunsaturated Fatty Acids in Depression.International journal of molecular sciences · 2024Review
- Review
- Increased intake of marine fish contributed to a decreased odds of comorbid depressive symptoms and coronary heart disease in Chinese adults.Frontiers in nutrition · 2024Article
- Depression and coronary heart disease: mechanisms, interventions, and treatments.Frontiers in psychiatry · 2024Review
- Effects of aerobic exercise on myocardial injury, NF-B expression, glucolipid metabolism and inflammatory factors in rats with coronary heart disease.Clinics (Sao Paulo, Brazil) · 2024Article
- Current Insights into the Use of Probiotics and Fatty Acids in Alleviating Depression.Microorganisms · 2023Review
- Symptoms that remain after depression treatment in patients with coronary heart disease.Journal of psychosomatic research · 2023Article
- Anti-Inflammatory Treatment Efficacy in Major Depressive Disorder: A Systematic Review of Meta-Analyses.Neuropsychiatric disease and treatment · 2023Review
- Review
- Current Perspectives on Pharmacological and Non-Pharmacological Interventions for the Inflammatory Mechanism of Unipolar Depression.Brain sciences · 2022Review
- The Risk of Fatal Arrhythmias Associated With Sertraline in Patients With Post-myocardial Infarction Depression.Cureus · 2022Review
- Omega-3 fatty acids in bipolar patients with a low omega-3 index and reduced heart rate variability: the "BIPO-3" trial.International journal of bipolar disorders · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveStudies of depressed psychiatric patients have suggested that antidepressant efficacy can be increased by adding eicosapentaenoic acid (EPA), one of the omega-3 fatty acids found in fish oils. The purpose of this study was to determine whether the addition of EPA improves the response to sertraline in depressed patients with or at high risk for coronary heart disease (CHD).
methodsBetween May 2014 and June 2018, 144 patients with DSM-5 major depressive disorder seen at the Washington University School of Medicine with or at high risk for CHD were randomized to receive either 50 mg/d of sertraline and 2 g/d of EPA or 50 mg/d of sertraline and corn oil placebo capsules for 10 weeks. The Beck Depression Inventory II (BDI-II) was the primary outcome measure.
resultsAfter 10 weeks of treatment, there were no differences between the arms on the mean baseline-adjusted BDI-II (placebo, 10.3; EPA, 12.1; P = .22), the 17-item Hamilton Depression Rating Scale (placebo, 7.2; EPA, 8.0; P = .40), or the 10-week remission rate (BDI-II score ≤ 8: placebo, 50.6%; EPA, 46.7%; odds ratio = 0.85; 95% CI, 0.43 to 1.68; P = .63).
conclusionsAugmentation of sertraline with 2 g/d of EPA for 10 weeks did not result in greater improvement in depressive symptoms compared to sertraline and corn oil placebo in patients with major depressive disorder and CHD or CHD risk factors. Identifying the characteristics of cardiac patients whose depression may benefit from omega-3 and clarifying the pathways linking omega-3 to improvement in depression symptoms are important directions for future research.
trial registrationClinicalTrials.gov identifier: NCT02021669; FDA IND registration number: 121107.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.